Table 1.

Baseline characteristics for randomized participants receiving study intervention

myo-Inositol (n = 44)Placebo (n = 41)Total (N = 85)P
Age, y0.52a
 Median58.558.058.0
 Range45.0–75.046.0–79.045.0–79.0
Race, n (%)0.59b
 White42 (95.5%)38 (92.7%)80 (94.1%)
 Asian2 (4.8%)3 (7.3%)5 (5.9%)
Body mass index, kg/m20.62a
 Median27.226.026.5
 Range21.1–36.321.0–35.221.0–36.3
Gender, n (%)0.35b
 Female10 (22.7%)13 (31.7%)23 (27.1%)
 Male34 (77.3%)28 (68.3%)62 (72.9%)
Smoking status, n (%)0.85b
 Current27 (61.4%)26 (63.4%)53 (62.4%)
 Former17 (38.6%)15 (36.6%)32 (37.6%)
Prior NSAID use0.49b
 No28 (63.6%)29 (70.7%)57 (67.1%)
 Yes16 (36.4%)12 (29.3%)28 (32.9%)
Dysplastic lesions identified0.74b
 1 dysplastic lesion22 (50.0%)19 (46.3%)41 (48.2%)
 >1 dysplastic lesions22 (50.0%)22 (53.7%)44 (51.8%)
Mucosal biopsies obtained0.62a
 Median6.07.07.0
 Range1.0–14.01.0–14.01.0–14.0
Most advanced histology, n (%)0.11b
 Mild dysplasia15 (34.1%)13 (31.7%)28 (32.9%)
 Moderate dysplasia28 (63.6%)22 (53.7%)50 (58.8%)
 Severe dysplasia1 (2.3%)6 (14.6%)7 (8.2%)
  • NOTE: No registered participants reported prior lung cancer. No registered participants reported Hispanic or Latino ethnicity.

  • aKruskal–Wallis test.

  • bχ2 test.